Does N-Acetylcysteine (Parvolex®) prophylaxis reduce the incidence of renal impairment after onpump Coronary Artery Bypass Graft surgery? A prospective randomised controlled trial

ISRCTN ISRCTN71629284
DOI https://doi.org/10.1186/ISRCTN71629284
Secondary identifying numbers 07/Q1403/17
Submission date
08/07/2007
Registration date
21/08/2007
Last edited
07/02/2012
Recruitment status
Stopped
Overall study status
Stopped
Condition category
Urological and Genital Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Donna Greenhalgh
Scientific

Consultant Anaesthetist
Wythenshawe Hospital
South Moore Road
Wythenshawe
Manchester
M23 9LT
United Kingdom

Phone +44 (0)161 291 2525
Email donna.greenhalgh@btopenworld.com

Study information

Study designProspective randomised double blind controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific title
Study acronymN-Acetylcysteine prophylaxis for onpump CABG
Study objectivesProhylatic use of N-Acetylcysteine will decrease the incidence of renal failure in patients undergoing onpump Coronary Artery Bypass Graft (CABG) surgery.
Ethics approval(s)Approved by South Manchester Research Ethics Committee (UK) on the 18th June 2007 (REC ref 07/Q1403/17).
Health condition(s) or problem(s) studiedRenal impairment
InterventionFor both groups, there will be no change in routine anaesthetic/surgical or post operative management.

The intervention group will be administered 2 g N-Acetylcysteine on the night before surgery (oral), 2 g at induction of anaesthesia (intravenous [IV]) and 2 g IV on the morning of first post operative day. The control group will receive placebos at the same time as the intervention group.

Patients will be followed up until discharge.

As of 07/02/2012, the trial was stopped in September 2010 due to problems with recruitment and the delay resulted in the trial being out of date.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)N-Acetylcysteine (Parvolex®)
Primary outcome measureCreatinine clearance and serum creatinine levels on second and fifth post operative day and on discharge.
Secondary outcome measuresLength of Intensive Care Unit (ICU) stay.
Overall study start date01/08/2007
Completion date31/07/2008
Reason abandoned (if study stopped)"Participant recruitment issue"

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Target number of participants224 (112 in each group) (Trial stopped in September 2010)
Key inclusion criteria1. Patients undergoing elective coronoray artery bypass surgery (onpump) at Wythenshawe Hospital
2. Aged 21 - 80 years
Key exclusion criteria1. Urgent or emergency cases
2. History of hypersensitivity to N-Acetylcysteine
3. Patients already taking N-Acetylcysteine
4. Patients with renal failure
Date of first enrolment01/08/2007
Date of final enrolment31/07/2008

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Consultant Anaesthetist
Manchester
M23 9LT
United Kingdom

Sponsor information

University Hospital of South Manchester NHS Foundation Trust (UK)
Hospital/treatment centre

Department of Research and Development
Wythenshawe Hospital
South Moore Road
Wythenshawe
Manchester
M23 9LT
England
United Kingdom

Phone +44 (0)161 291 5775
Email andrew.maines@manchester.ac.uk
Website http://www.smuht.nwest.nhs.uk/
ROR logo "ROR" https://ror.org/00he80998

Funders

Funder type

Government

University Hospital of South Manchester NHS Foundation Trust (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan